Group 1 - The Hengqin New Area concept index rose by 2.44%, ranking 8th among concept sectors, with 37 stocks increasing in value [1][2] - Notable gainers included Palm Holdings, Zhuhai Port, and *ST Jianyi, which hit the daily limit, while ST Xiangxue, *ST Diwei, and Huajin Capital also saw significant increases of 9.73%, 7.92%, and 5.01% respectively [1][2] - The sector experienced a net inflow of 373 million yuan, with 22 stocks receiving net inflows, and 6 stocks attracting over 30 million yuan each, led by Zhuhai Port with a net inflow of 143 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included *ST Jianyi, Zhuhai Port, and ST Lingnan, with net inflow ratios of 81.21%, 50.47%, and 29.49% respectively [3][4] - The trading volume and turnover rates for key stocks were highlighted, with Zhuhai Port showing a turnover rate of 5.16% and a significant net inflow of 142.76 million yuan [3][4] - Decliners in the sector included Zhuhai Mian Group, Shenguang Group, and Letong Co., which saw declines of 2.85%, 1.30%, and 1.24% respectively [1][5]

Group 1 - The new merger and acquisition regulations have been officially implemented by the China Securities Regulatory Commission, simplifying review processes and enhancing regulatory inclusiveness [5][9] - The market reacted positively to the new regulations, with the Wande restructuring index leading gains and nearly 10 constituent stocks hitting the daily limit [6][9] - Notable stocks that surged include Wuxin Equipment, which rose by 24.42%, and Meilihua Electric, which increased by 20% [7] Group 2 - The real estate sector showed resilience amid expectations of interest rate cuts, while the shipping and port sectors experienced significant gains, with Nanjing Port achieving five consecutive trading limits [2][6] - Conversely, the robotics and PEEK materials sectors faced collective declines, with stocks like Longxi Co. hitting the daily limit down [3][4] - The ST sector also saw a wave of limit-up stocks, with nearly 20 stocks reaching their daily limit [8][9]

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

证券代码：300147 证券简称：ST 香雪 公告编号：2025-029 广州市香雪制药股份有限公司 关于 TAEST1901 注射液获得药物临床试验批准的公告 二、药品的研发情况 香雪生命科学已建立 TCR-T 完整的技术平台及工艺，具有完整的自主知识产 权，TAEST1901 注射液是香雪生命科学研发管线的第二个产品，TAEST1901 针对的 靶点是 HLA-A*02:01 及 AFP 抗原肽组成的复合物，使用慢病毒转导自体 T 细胞， 表达 AFP 抗原特异性的 TCR。 2022 年 4 月，国家药品监督管理局批准 TAEST1901 注射液的新药临床注册申 请，申请适应症为用于治疗组织基因型为 HLA-A*02:01，肿瘤抗原 AFP 表达为阳 性的晚期肝癌或其它晚期肿瘤。目前，TAEST1901 注射液正在进行首个适应症晚 期肝癌的 I 期临床试验。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）子公司香雪生命科学技 术（广东）有限公司（以下简称"香雪生命科学"）收到国家药品监督管理局签 发的《 ...

Investment Rating - The report maintains a strong rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [5]. Core Insights - The report highlights a significant breakthrough in sepsis treatment through immune homeostasis therapy, specifically recommending attention to Yuan Da Pharmaceutical's STC3141 [4][16]. - Sepsis is a common complication in critically ill patients, with a high global prevalence of approximately 49 million cases and an annual death toll of around 11 million [4][21]. - The report emphasizes the challenges in developing new therapies for sepsis due to its complex pathophysiology and the high failure rate of clinical trials [4][43]. - STC3141 has shown promising results in clinical trials, demonstrating a significant reduction in SOFA scores, particularly in high-dose groups compared to placebo [4][59]. Summary by Sections Sepsis Overview - Sepsis is a severe condition resulting from infections, with a high mortality rate, particularly in ICU patients in China, where the prevalence is about 20.6% and the 90-day mortality rate is 35.5% [4][21]. - The complexity of sepsis mechanisms and patient heterogeneity complicates the development of effective treatments [4][43]. Treatment Developments - The immune homeostasis therapy represented by STC3141 aims to address the underlying immune dysregulation in sepsis, marking a significant advancement in treatment strategies [4][49]. - Clinical trials for STC3141 have been successful, achieving primary endpoints and showing good safety and tolerability profiles [4][59]. Market Trends - The pharmaceutical sector has shown signs of recovery after a prolonged adjustment period, with innovation in drug development being a key focus for investment [5][8]. - The report suggests that the innovation-driven pharmaceutical sector is likely to maintain strong performance throughout the year, with specific recommendations for leading companies and those with clear catalysts [4][5].

证券代码:300147 证券简称:ST 香雪 公告编号:2025—028 广州市香雪制药股份有限公司 关于临时管理人公开选聘中介机构结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 11 日，广州市中级人民法院（以下简称"广州中院"）作出（2 025）粤 01 破申 54 号《决定书》《指定临时管理人决定书》，决定对广州市香 雪制药股份有限公司（以下简称"公司"）进行预重整，并指定北京市金杜(广 州)律师事务所(主办机构)、广东东方昆仑律师事务所作为联合体担任公司预重 整期间的临时管理人（以下简称"临时管理人"）。 为尽快开展资产调查、债务核查等工作，充分识别公司是否具备重整价值与 重整可能，依据《广州市中级人民法院关于破产重整案件审理指引（试行）》第 三十二条，临时管理人通过公开选聘方式确定公司预重整案（以下简称"本案"） 审计机构、评估机构及财务顾问机构（以下合称"中介机构"）。具体内容详见 2025 年 4 月 18 日巨潮网披露的《关于临时管理人公开选聘审计、评估及财务顾 问机构的公告》（公告编号:2025—013）。 ...

Core Viewpoint - ST Xiangxue (300147.SZ) reported a decline in revenue and profit for 2024, indicating a low point in business operations, but there are positive aspects in business management, new drug development, and corporate governance that may signal future growth opportunities for investors [1][2]. Business Operations - The company's largest revenue segment, traditional Chinese medicine materials, saw a year-on-year revenue increase of 25.69%, reaching 936 million yuan, contributing 280 million yuan in gross profit [1]. - ST Xiangxue has established a comprehensive industrial chain in the traditional Chinese medicine sector, including production and sales, with cultivation bases in regions such as Ningxia, Sichuan, Yunnan, and Guangdong [1]. New Drug Development - The company is advancing its first-class new drug TAEST16001 injection, which has entered the phase II clinical trial and was presented at the ASCO annual meeting [2]. - TAEST16001 is the first TCR-T cell therapy drug in China to receive IND approval, targeting advanced esophageal cancer and non-small cell lung cancer [2]. - The drug has shown a best response rate of 50% and a median progression-free survival of 5.9 months, indicating significant clinical efficacy and manageable safety [2]. Corporate Restructuring - In April, the company entered a pre-restructuring process, with a temporary administrator appointed to manage debt claims and conduct audits and evaluations [3]. - The restructuring plan aims to improve the company's asset-liability structure and enhance its operational and profitability capabilities, facilitating a return to sustainable and high-quality development [3].

Core Insights - ST Xiangxue (300147.SZ) reported a total operating revenue of 1.859 billion yuan for 2024, ranking 39th among disclosed peers, which represents a decrease of 441 million yuan or 19.16% year-on-year [1] - The company recorded a net profit attributable to shareholders of -859 million yuan, ranking 68th among peers, a decline of 470 million yuan compared to the same period last year [1] - Operating cash flow showed a net inflow of 18.17 million yuan, ranking 53rd among peers, down 245 million yuan or 93.10% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio stands at 80.81%, ranking 66th among peers, an increase of 8.75 percentage points from the previous year [3] - The latest gross profit margin is 24.36%, ranking 64th among peers [3] - Return on equity (ROE) is reported at -81.39%, ranking 66th among peers, a decrease of 61.18 percentage points year-on-year [3] - The diluted earnings per share is -1.30 yuan, ranking 67th among peers, a reduction of 0.71 yuan compared to the same period last year [3] - The total asset turnover ratio is 0.24 times, ranking 60th among peers, a decline of 0.04 times or 13.29% year-on-year [3] - The inventory turnover ratio is reported at 3.74 times [3] Shareholder Structure - The number of shareholders is 63,500, with the top ten shareholders holding 196 million shares, accounting for 29.62% of the total share capital [3] - The largest shareholder is Guangzhou Kunlun Investment Co., Ltd., holding 22.5 million shares [3] - Other notable shareholders include Guangzhou Luogang Water Supply Co., Ltd. (4.06 million shares) and various institutional investors [3]

广州市香雪制药股份有限公司 审计报告 德皓审字[2025]00001460 号 北 京 德 皓 国 际 会计师事务所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 广州市香雪制药股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-8 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-117 | 第 1 页 ...

广州市香雪制药股份有限公司 内部控制审计报告 德皓内字[2025]00000122 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 广州市香雪制药股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 内 部 控 制 审 计 报 告 德皓内字[2025]00000122 号 广州市香雪制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了广州市香雪制药股份有限公司（以下简称香雪制 药）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部 ...